Literature DB >> 18636631

Velo-cardio-facial syndrome: 30 Years of study.

Robert J Shprintzen1.   

Abstract

Velo-cardio-facial syndrome is one of the names that has been attached to one of the most common multiple anomaly syndromes in humans. The labels DiGeorge sequence, 22q11 deletion syndrome, conotruncal anomalies face syndrome, CATCH 22, and Sedlacková syndrome have all been attached to the same disorder. Velo-cardio-facial syndrome has an expansive phenotype with more than 180 clinical features described that involve essentially every organ and system. The syndrome has drawn considerable attention because a number of common psychiatric illnesses are phenotypic features including attention deficit disorder, schizophrenia, and bipolar disorder. The expression is highly variable with some individuals being essentially normal at the mildest end of the spectrum, and the most severe cases having life-threatening and life-impairing problems. The syndrome is caused by a microdeletion from chromosome 22 at the q11.2 band. Although the large majority of affected individuals have identical 3 megabase deletions, less than 10% of cases have smaller deletions of 1.5 or 2.0 megabases. The 3 megabase deletion encompasses a region containing 40 genes. The syndrome has a population prevalence of approximately 1:2,000 in the United States, although incidence is higher. Although initially a clinical diagnosis, today velo-cardio-facial syndrome can be diagnosed with extremely high accuracy by fluorescence in situ hybridization and several other laboratory techniques. Clinical management is age dependent with acute medical problems such as congenital heart disease, immune disorders, feeding problems, cleft palate, and developmental disorders occupying management in infancy and preschool years. Management shifts to cognitive, behavioral, and learning disorders during school years, and then to the potential for psychiatric disorders including psychosis in late adolescence and adult years. Although the majority of people with velo-cardio-facial syndrome do not develop psychosis, the risk for severe psychiatric illness is 25 times higher for people affected with velo-cardio-facial syndrome than that of the general population. Therefore, interest in understanding the nature of psychiatric illness in the syndrome remains strong.

Entities:  

Mesh:

Year:  2008        PMID: 18636631      PMCID: PMC2805186          DOI: 10.1002/ddrr.2

Source DB:  PubMed          Journal:  Dev Disabil Res Rev        ISSN: 1940-5529


  61 in total

1.  Dysphagia in children with a 22q11.2 deletion: unusual pattern found on modified barium swallow.

Authors:  P S Eicher; D M McDonald-Mcginn; C A Fox; D A Driscoll; B S Emanuel; E H Zackai
Journal:  J Pediatr       Date:  2000-08       Impact factor: 4.406

2.  TBX1 is responsible for cardiovascular defects in velo-cardio-facial/DiGeorge syndrome.

Authors:  S Merscher; B Funke; J A Epstein; J Heyer; A Puech; M M Lu; R J Xavier; M B Demay; R G Russell; S Factor; K Tokooya; B S Jore; M Lopez; R K Pandita; M Lia; D Carrion; H Xu; H Schorle; J B Kobler; P Scambler; A Wynshaw-Boris; A I Skoultchi; B E Morrow; R Kucherlapati
Journal:  Cell       Date:  2001-02-23       Impact factor: 41.582

3.  Craniofacial morphology in the velo-cardio-facial syndrome.

Authors:  M Arvystas; R J Shprintzen
Journal:  J Craniofac Genet Dev Biol       Date:  1984

4.  Palatal and pharyngeal anomalies in craniofacial syndromes.

Authors:  R J Shprintzen
Journal:  Birth Defects Orig Artic Ser       Date:  1982

5.  The velo-cardio-facial syndrome: a clinical and genetic analysis.

Authors:  R J Shprintzen; R B Goldberg; D Young; L Wolford
Journal:  Pediatrics       Date:  1981-02       Impact factor: 7.124

6.  22q11 deletion and polymicrogyria--cause or coincidence?

Authors:  S Worthington; A Turner; J Elber; P I Andrews
Journal:  Clin Dysmorphol       Date:  2000-07       Impact factor: 0.816

Review 7.  Velo-cardio-facial syndrome: a distinctive behavioral phenotype.

Authors:  R J Shprintzen
Journal:  Ment Retard Dev Disabil Res Rev       Date:  2000

8.  Evidence for association between novel polymorphisms in the PRODH gene and schizophrenia in a Chinese population.

Authors:  Tao Li; Xiaohong Ma; Pak C Sham; Xueli Sun; Xun Hu; Qiang Wang; Huaqing Meng; Wei Deng; Xiehe Liu; Robin M Murray; David A Collier
Journal:  Am J Med Genet B Neuropsychiatr Genet       Date:  2004-08-15       Impact factor: 3.568

9.  Frontal and caudate alterations in velocardiofacial syndrome (deletion at chromosome 22q11.2).

Authors:  Wendy R Kates; Courtney P Burnette; Brandy A Bessette; Bradley S Folley; Leslie Strunge; Ethylin W Jabs; Godfrey D Pearlson
Journal:  J Child Neurol       Date:  2004-05       Impact factor: 1.987

10.  A new syndrome involving cleft palate, cardiac anomalies, typical facies, and learning disabilities: velo-cardio-facial syndrome.

Authors:  R J Shprintzen; R B Goldberg; M L Lewin; E J Sidoti; M D Berkman; R V Argamaso; D Young
Journal:  Cleft Palate J       Date:  1978-01
View more
  143 in total

Review 1.  Epigenetic mechanisms in cardiac development and disease.

Authors:  Marcus Vallaster; Caroline Dacwag Vallaster; Sean M Wu
Journal:  Acta Biochim Biophys Sin (Shanghai)       Date:  2012-01       Impact factor: 3.848

2.  Shape-based classification of 3D facial data to support 22q11.2DS craniofacial research.

Authors:  Katarzyna Wilamowska; Jia Wu; Carrie Heike; Linda Shapiro
Journal:  J Digit Imaging       Date:  2012-06       Impact factor: 4.056

Review 3.  Genome-wide approaches to schizophrenia.

Authors:  Jubao Duan; Alan R Sanders; Pablo V Gejman
Journal:  Brain Res Bull       Date:  2010-04-28       Impact factor: 4.077

Review 4.  How insights from cardiovascular developmental biology have impacted the care of infants and children with congenital heart disease.

Authors:  Alvin J Chin; Jean-Pierre Saint-Jeannet; Cecilia W Lo
Journal:  Mech Dev       Date:  2012-05-26       Impact factor: 1.882

5.  Persistent gating deficit and increased sensitivity to NMDA receptor antagonism after puberty in a new mouse model of the human 22q11.2 microdeletion syndrome: a study in male mice.

Authors:  Michael Didriksen; Kim Fejgin; Simon R O Nilsson; Michelle R Birknow; Hannah M Grayton; Peter H Larsen; Jes B Lauridsen; Vibeke Nielsen; Pau Celada; Noemi Santana; Pekka Kallunki; Kenneth V Christensen; Thomas M Werge; Tine B Stensbøl; Jan Egebjerg; Francois Gastambide; Francesc Artigas; Jesper F Bastlund; Jacob Nielsen
Journal:  J Psychiatry Neurosci       Date:  2017-01       Impact factor: 6.186

6.  Social cognitive training in adolescents with chromosome 22q11.2 deletion syndrome: feasibility and preliminary effects of the intervention.

Authors:  V Shashi; W Harrell; S Eack; C Sanders; A McConkie-Rosell; M S Keshavan; M J Bonner; K Schoch; S R Hooper
Journal:  J Intellect Disabil Res       Date:  2015-04-14

Review 7.  The neural crest in cardiac congenital anomalies.

Authors:  Anna Keyte; Mary Redmond Hutson
Journal:  Differentiation       Date:  2012-05-15       Impact factor: 3.880

8.  Congenital Heart Defects and Dysmorphic Facial Features in Patients Suspicious of 22q11.2 Deletion Syndrome in Southern Brazil.

Authors:  Bruna Lixinski Diniz; Andressa Schneiders Santos; Andressa Barreto Glaeser; Bruna Baierle Guaraná; Cláudia Fernandes Lorea; Juliana Alves Josahkian; Janaína Huber; Rafael Fabiano Machado Rosa; Paulo Ricardo Gazzola Zen
Journal:  J Pediatr Genet       Date:  2020-06-17

9.  White matter abnormalities in 22q11.2 deletion syndrome: preliminary associations with the Nogo-66 receptor gene and symptoms of psychosis.

Authors:  Matthew D Perlstein; Moeed R Chohan; Ioana L Coman; Kevin M Antshel; Wanda P Fremont; Matthew H Gnirke; Zora Kikinis; Frank A Middleton; Petya D Radoeva; Martha E Shenton; Wendy R Kates
Journal:  Schizophr Res       Date:  2013-12-08       Impact factor: 4.939

Review 10.  Bullying and psychosis: The impact of chronic traumatic stress on psychosis risk in 22q11.2 deletion syndrome - a uniquely vulnerable population.

Authors:  Danessa Mayo; Khalima A Bolden; Tony J Simon; Tara A Niendam
Journal:  J Psychiatr Res       Date:  2019-04-15       Impact factor: 4.791

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.